NASDAQ:GOVX GeoVax Labs Q3 2026 Earnings Date & Estimates $0.14 -0.01 (-9.44%) Closing price 11/9/2026 04:00 PM EasternExtended Trading$0.14 0.00 (-3.50%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. GeoVax Labs is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from GeoVax Labs in Q3 2026GeoVax Labs is expected to post earnings of -$1.09 per share. In the same quarter a year earlier GeoVax Labs reported -$7.75 per share. GeoVax Labs last reported on July 27, 2026, posting -$0.97 per share and beating the -$2.16 consensus estimate. GeoVax Labs has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.09Prior-Year EPS-$7.75Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.97 (Beat by +$1.19)EPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report GeoVax Labs Q3 2026 Earnings FAQ When does GeoVax Labs report Q3 2026 earnings? GeoVax Labs (NASDAQ:GOVX) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is GeoVax Labs' Q3 2026 earnings call? GeoVax Labs' Q3 2026 earnings conference call is scheduled for Thursday, November 19, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for GeoVax Labs? Analysts expect GeoVax Labs to post earnings of -$1.09 per share for Q3 2026. GeoVax Labs Earnings HeadlinesGeoVax Labs (GOVX) Expected to Post Earnings on Thursday1 hour ago | americanbankingnews.comGeoVax Announces 1-for-24 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid RequirementNovember 9 at 1:47 PM | finance.yahoo.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars. | Behind the Markets (Ad)GeoVax Enters Into $1 Million Revolving Loan AgreementOctober 26, 2026 | finance.yahoo.comGeoVax Enters Into $1 Million Revolving Loan AgreementOctober 26, 2026 | finance.yahoo.comGeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026October 6, 2026 | theglobeandmail.comSee More GeoVax Labs Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GeoVax Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeoVax Labs and other key companies, straight to your email. Email Address About GeoVax LabsGeoVax Labs (NASDAQ:GOVX), Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases. The company has also pursued immunotherapy approaches for cancer, including candidates intended to stimulate immune responses against tumor-associated targets. Founded in 2001 and headquartered in Atlanta, Georgia, GeoVax conducts research and development through collaborations with government agencies, academic institutions, and industry partners. The company’s programs are primarily in preclinical or clinical development, and its lead programs and geographic reach may change as studies and partnerships advance. GeoVax is led by David Dodd, who serves as chairman and chief executive officer.View GeoVax Labs ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength RemainsThe Ugly Truth Behind SoundHound’s Q3 Results Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
